Press releaseGlobe Newswire
Nexalin Technology
NXL · NASDAQ
$2.14−$0.22 (−9.32%)TodayMarket closed ·
Prev close $2.36
Latest news
- NewsAvi Kapoor
Dow Jumps Over 300 Points; US Economy Adds 29,000 Jobs In September
- NewsAvi Kapoor
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
- NewsVandana Singh
Why Is Nexalin Technology Stock Gaining Thursday?
- Press releaseGlobe Newswire
These Stocks Roar into October with Fresh Catalysts
- NewsAvi Kapoor
Dow Falls Over 200 Points; Micron Earnings Top Views
- News
Nexalin Signs 10-Year Exclusive Distribution Deal With Inovanexa Medical Technologies Covering Seven Latin American Markets
- Press releaseGlobe Newswire
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
- Press releaseGlobe Newswire
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
- Press releaseGlobe Newswire
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
- Press releaseGlobe Newswire
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
- Press releaseGlobe Newswire
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
- NewsAkanksha Bakshi
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsVandana Singh
EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsVandana Singh
EXCLUSIVE: Penny Stock Nexalin Advances Pivotal Trial Aiming To Tackle Severe Insomnia
- NewsVandana Singh
EXCLUSIVE: Nexalin Launches AI-Powered Virtual Clinic For Brain Health For Home Settings
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAnusuya Lahiri
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.